BRPI0407101A - Vacinas meningocócicas mucosais - Google Patents

Vacinas meningocócicas mucosais

Info

Publication number
BRPI0407101A
BRPI0407101A BR0407101-8A BRPI0407101A BRPI0407101A BR PI0407101 A BRPI0407101 A BR PI0407101A BR PI0407101 A BRPI0407101 A BR PI0407101A BR PI0407101 A BRPI0407101 A BR PI0407101A
Authority
BR
Brazil
Prior art keywords
mucosal
compositions
delivery
chitosan
conjugated
Prior art date
Application number
BR0407101-8A
Other languages
English (en)
Inventor
Giuseppe Del Giudice
Barbara Baudner
Original Assignee
Chiron Srl
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Srl, Univ Leiden filed Critical Chiron Srl
Priority claimed from PCT/IB2004/000673 external-priority patent/WO2004067033A1/en
Publication of BRPI0407101A publication Critical patent/BRPI0407101A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"VACINAS MENINGOCóCICAS MUCOSAIS". A invenção proporciona composições imunogênicas para distribuição mucosal compreendendo sacarídeos capsulares de pelo menos dois sorogrupos A, C, W135 e Y de N. meningitidis. é preferido que os sacarídeos capsulares nas composições da invenção sejam conjugados a proteína (s) veículo e/ou sejam oligossacarídeos. Antígenos de oligossacarídeo conjugados são particularmente preferidos. A invenção também proporciona composições imunogênicas compreendendo (a) um antígeno de sacarídeo capsular do sorogrupo C de N. meningitidis e (b) um adjuvante de quitosana. A composição compreende, de preferência, (c) um ou mais de outros antígenos e/ou (d) um ou mais de outros adjuvantes. As composições são particularmente adequadas para distribuição mucosal, incluindo distribuição intranasal. O uso de quitosana e/ou adjuvantes de toxina de ADP-ribosilação destoxificada intensifica as respostas imunes mucosais anti-meningocócicas e podem desviar a predisposição Th1/Th2 das respostas.
BR0407101-8A 2003-01-30 2004-01-30 Vacinas meningocócicas mucosais BRPI0407101A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0302218.3A GB0302218D0 (en) 2003-01-30 2003-01-30 Vaccine formulation & Mucosal delivery
PCT/IB2003/002382 WO2003094834A2 (en) 2002-05-14 2003-05-14 Mucosal vaccines with chitosan adjuvant and meningococcal antigens
PCT/IB2004/000673 WO2004067033A1 (en) 2002-05-14 2004-01-30 Mucosal meningococcal vaccines

Publications (1)

Publication Number Publication Date
BRPI0407101A true BRPI0407101A (pt) 2006-01-24

Family

ID=9952172

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0310062-6A BR0310062A (pt) 2002-05-14 2003-05-14 Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos
BR0407101-8A BRPI0407101A (pt) 2003-01-30 2004-01-30 Vacinas meningocócicas mucosais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0310062-6A BR0310062A (pt) 2002-05-14 2003-05-14 Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos

Country Status (13)

Country Link
US (1) US8926992B2 (pt)
EP (2) EP1506008B1 (pt)
JP (4) JP4696260B2 (pt)
CN (1) CN100579580C (pt)
AU (1) AU2003233128B2 (pt)
BR (2) BR0310062A (pt)
CA (1) CA2485992C (pt)
ES (2) ES2328128T3 (pt)
GB (1) GB0302218D0 (pt)
MX (1) MXPA05007886A (pt)
NZ (1) NZ536715A (pt)
RU (2) RU2004136299A (pt)
WO (1) WO2003094834A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
CA2514667C (en) * 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
AU2011224064A1 (en) * 2003-10-02 2011-10-06 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
AU2012203419B2 (en) * 2005-06-27 2014-06-26 Glaxosmithkline Biologicals S.A. Immunogenic composition
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US20100150960A1 (en) * 2006-09-22 2010-06-17 The United States Of America, As Represented By The Secretary,Department Of Health And Human Servi Compositions and methods for chitosan enhanced immune response
EP2066354B1 (en) 2006-09-29 2013-04-17 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2009014774A1 (en) * 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
BR122016015627A2 (pt) * 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
EP4112074A1 (en) 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP3363462A1 (en) * 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11027005B2 (en) * 2016-10-20 2021-06-08 Km Biologics Co., Ltd. Method for producing Hib conjugate vaccine using PRP with lowered molecular weight
WO2018089322A1 (en) * 2016-11-08 2018-05-17 Colgate-Palmolive Company Oral care compositions
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN113646438A (zh) * 2019-01-11 2021-11-12 西北大学 在原核生物细胞裂解物中合成生物缀合物疫苗
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN116033894A (zh) * 2020-05-22 2023-04-28 卡洛斯·阿尔贝托·里维罗斯 用于减少气道粘膜中的病毒复制的系统、方法和药物使用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
JP5124066B2 (ja) * 1999-03-24 2013-01-23 イギリス国 ポリカチオン性炭水化物のワクチンにおける免疫賦活剤としての使用
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
US20010026800A1 (en) 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
CZ20024224A3 (cs) 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0029919D0 (en) * 2000-12-07 2001-01-24 Chiron Spa Helicobacter pylori prime & boost vaccination
SI21352A (sl) * 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CA2439111A1 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1438323A4 (en) 2001-10-03 2007-08-01 Novartis Vaccines & Diagnostic ADJUVOUS MENINGOCOCCUS COMPOSITIONS
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
WO2003059385A2 (en) * 2002-01-14 2003-07-24 Chiron Corporation Hiv vaccine and method of use
US7249709B2 (en) * 2002-03-18 2007-07-31 Koninklijke Philips Electronics N.V. Holder for papers of value, and method of registering the contents thereof
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
NZ536859A (en) 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis

Also Published As

Publication number Publication date
US8926992B2 (en) 2015-01-06
BR0310062A (pt) 2005-02-15
JP2012046550A (ja) 2012-03-08
RU2349342C2 (ru) 2009-03-20
MXPA05007886A (es) 2005-09-21
EP1506008A2 (en) 2005-02-16
EP1587538B1 (en) 2014-04-02
JP2015061879A (ja) 2015-04-02
CA2485992A1 (en) 2003-11-20
NZ536715A (en) 2007-02-23
RU2005127200A (ru) 2006-06-10
JP2005525415A (ja) 2005-08-25
ES2470765T3 (es) 2014-06-24
WO2003094834A3 (en) 2004-05-21
EP1587538A1 (en) 2005-10-26
GB0302218D0 (en) 2003-03-05
AU2003233128B2 (en) 2008-10-09
AU2003233128A1 (en) 2003-11-11
US20060051378A1 (en) 2006-03-09
JP4696260B2 (ja) 2011-06-08
CN1767853A (zh) 2006-05-03
EP1506008B1 (en) 2009-07-22
CN100579580C (zh) 2010-01-13
ES2328128T3 (es) 2009-11-10
JP2016104813A (ja) 2016-06-09
RU2004136299A (ru) 2006-03-10
CA2485992C (en) 2013-07-09
WO2003094834A2 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
BRPI0407101A (pt) Vacinas meningocócicas mucosais
WO2004067030A3 (en) Injectable vaccines against multiple meningococcal serogroups
BRPI0510104A8 (pt) Imunização contra sorogrupo meningocócico y que usa proteínas
CR10123A (es) Vacuna.
WO2007026249A3 (en) Multiple vaccination including serogroup c meningococcus
EP4649956A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
BRPI0408167A (pt) conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
CA2435681A1 (en) Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2005032583A3 (en) Liquid vaccines for multiple meningococcal serogroups
DE122010000042I1 (de) Solubilisierung von capsulären Polysacchariden
WO2001037863A3 (en) Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen
WO2004041157A3 (en) Group b streptococcus vaccine
BRPI0818545A2 (pt) formulações de vacinais meningocócicas
BRPI0410341B8 (pt) conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
WO2022101745A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BRPI0516770A (pt) vacina e conjugados de proteìna - derivados de polissacarìdeo de meningocócico multivalente
Haneberg et al. Bacteria-derived particles as adjuvants for non-replicating nasal vaccines
BRPI0516372A (pt) conjugados de polissacarìdeo-proteìna derivatizados meningocócicos multivalentes e vacina
MX2025012232A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
MX2025005300A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
MX2025011233A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: UNIVERSITEIT LEIDEN (NL) , NOVARTIS VACCINES AND D

Free format text: ALTERADO DE: CHIRON SRL.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.